Drug Discovery and Design Center, The Center for Chemical Biology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China.
J Med Chem. 2022 Feb 10;65(3):2174-2190. doi: 10.1021/acs.jmedchem.1c01686. Epub 2022 Jan 28.
The unique proline isomerase peptidyl-prolyl isomerase NIMA-interacting-1 (Pin1) is reported to activate numerous cancer-driving pathways simultaneously, and aberrant Pin1 activation is present in many human cancers. Here, we identified a novel hit compound, , that covalently modified Pin1 at Cys113 with an half-maximal inhibitory concentration (IC) of 1.33 ± 0.07 μM through screening an in-house library. Crystallographic study drove the process of structure-guided optimization and led to the potent inhibitor with an IC of 0.067 ± 0.03 μM. We obtained four co-crystal structures of Pin1 complexed with inhibitors that elucidated the detailed binding mode of the derivatives with Pin1. Interestingly, the co-crystal of Pin1 with obtained by co-crystallization revealed the conformational change of Gln129 induced by the inhibitor. Furthermore, effectively inhibited the proliferation and downregulated the Pin1 substrates in MDA-MB-231 cells. Collectively, we developed a potent covalent inhibitor of Pin1, , which could be an effective probe for studying the functional roles of Pin1.
研究报道,脯氨酸异构酶肽脯氨酰基异构酶 NIMA 相互作用蛋白 1(Pin1)是一种独特的异构酶,能够同时激活许多致癌途径,并且在许多人类癌症中存在异常的 Pin1 激活。在这里,我们通过筛选内部文库,鉴定出一种新型命中化合物 ,其通过半最大抑制浓度(IC)为 1.33±0.07μM 与 Pin1 的 Cys113 发生共价修饰。晶体学研究推动了结构引导优化的过程,并导致了具有 IC 为 0.067±0.03μM 的有效抑制剂 。我们获得了四个与抑制剂结合的 Pin1 复合物的共晶结构,阐明了衍生物与 Pin1 的详细结合模式。有趣的是,通过共结晶获得的 Pin1 与 的共晶揭示了抑制剂诱导的 Gln129 构象变化。此外, 在 MDA-MB-231 细胞中有效抑制了增殖并下调了 Pin1 底物。总之,我们开发了一种有效的 Pin1 共价抑制剂 ,它可以作为研究 Pin1 功能作用的有效探针。